235 related articles for article (PubMed ID: 21895409)
21. BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.
Sherbenou DW; Hantschel O; Kaupe I; Willis S; Bumm T; Turaga LP; Lange T; Dao KH; Press RD; Druker BJ; Superti-Furga G; Deininger MW
Blood; 2010 Oct; 116(17):3278-85. PubMed ID: 20519627
[TBL] [Abstract][Full Text] [Related]
22. A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.
Ernst T; Gruber FX; Pelz-Ackermann O; Maier J; Pfirrmann M; Müller MC; Mikkola I; Porkka K; Niederwieser D; Hochhaus A; Lange T
Haematologica; 2009 Sep; 94(9):1227-35. PubMed ID: 19608684
[TBL] [Abstract][Full Text] [Related]
23. Detection of BCR-ABL mutations and resistance to imatinib mesylate.
Branford S; Hughes T
Methods Mol Med; 2006; 125():93-106. PubMed ID: 16502579
[TBL] [Abstract][Full Text] [Related]
24. Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India.
Bagadi S; Saikia T; Pany A; Das B
Clin Lab; 2011; 57(7-8):619-23. PubMed ID: 21888027
[TBL] [Abstract][Full Text] [Related]
25. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.
Branford S; Rudzki Z; Walsh S; Parkinson I; Grigg A; Szer J; Taylor K; Herrmann R; Seymour JF; Arthur C; Joske D; Lynch K; Hughes T
Blood; 2003 Jul; 102(1):276-83. PubMed ID: 12623848
[TBL] [Abstract][Full Text] [Related]
26. Successful treatment with nilotinib after imatinib failure in a CML patient with a four-way Ph chromosome translocation and point mutations in BCR/ABL gene.
Okada M; Satake A; Kaida K; Taniguchi K; Yoshihara S; Ikegame K; Tamaki H; Soma T; Fujimori Y; Ogawa H
Int J Hematol; 2011 Feb; 93(2):243-246. PubMed ID: 21279819
[TBL] [Abstract][Full Text] [Related]
27. BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?
Gruber FX; Lundán T; Goll R; Silye A; Mikkola I; Rekvig OP; Knuutila S; Remes K; Gedde-Dahl T; Porkka K; Hjorth-Hansen H
Med Oncol; 2012 Mar; 29(1):219-26. PubMed ID: 21221851
[TBL] [Abstract][Full Text] [Related]
28. Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.
Markose P; Chendamarai E; Balasubramanian P; Velayudhan SR; Srivastava VM; Mathews V; George B; Viswabandya A; Srivastava A; Chandy M
Leuk Lymphoma; 2009 Dec; 50(12):2092-5. PubMed ID: 19925053
[No Abstract] [Full Text] [Related]
29. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
[TBL] [Abstract][Full Text] [Related]
30. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.
Al-Ali HK; Heinrich MC; Lange T; Krahl R; Mueller M; Müller C; Niederwieser D; Druker BJ; Deininger MW
Hematol J; 2004; 5(1):55-60. PubMed ID: 14745431
[TBL] [Abstract][Full Text] [Related]
31. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
[TBL] [Abstract][Full Text] [Related]
32. Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia.
Sherbenou DW; Hantschel O; Turaga L; Kaupe I; Willis S; Bumm T; Press RD; Superti-Furga G; Druker BJ; Deininger MW
Leukemia; 2008 Jun; 22(6):1184-90. PubMed ID: 18354488
[TBL] [Abstract][Full Text] [Related]
33. ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan.
Awidi A; Ababneh N; Magablah A; Bsoul N; Mefleh R; Marei L; Abbasi S
Genet Test Mol Biomarkers; 2012 Nov; 16(11):1317-21. PubMed ID: 23009571
[TBL] [Abstract][Full Text] [Related]
34. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
35. Incidence of Bcr-Abl kinase domain mutations in imatinib refractory chronic myeloid leukemia patients from South India.
Kagita S; Uppalapati S; Jiwatani S; Linga VG; Gundeti S; Nagesh N; Digumarti R
Tumour Biol; 2014 Jul; 35(7):7187-93. PubMed ID: 24763825
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance.
Chahardouli B; Zaker F; Mousavi SA; Kazemi A; Ostadali M; Nadali F; Rostami S; Alimoghaddam K; Ghavamzade A
Hematology; 2013 May; 18(3):158-62. PubMed ID: 23540562
[TBL] [Abstract][Full Text] [Related]
37. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.
Roche-Lestienne C; Soenen-Cornu V; Grardel-Duflos N; Laï JL; Philippe N; Facon T; Fenaux P; Preudhomme C
Blood; 2002 Aug; 100(3):1014-8. PubMed ID: 12130516
[TBL] [Abstract][Full Text] [Related]
38. Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib.
Soverini S; Martinelli G; Amabile M; Poerio A; Bianchini M; Rosti G; Pane F; Saglio G; Baccarani M; ;
Clin Chem; 2004 Jul; 50(7):1205-13. PubMed ID: 15107311
[TBL] [Abstract][Full Text] [Related]
39. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
Branford S; Melo JV; Hughes TP
Blood; 2009 Dec; 114(27):5426-35. PubMed ID: 19880502
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR-ABL kinase domain mutations affect patient survival? First multicenter Argentinean study.
Bengió RM; Riva ME; Moiraghi B; Lanari E; Milone J; Ventriglia V; Bullorsky E; Tezanos Pinto Md; Murro H; Bianchini M; Larripa I
Leuk Lymphoma; 2011 Sep; 52(9):1720-6. PubMed ID: 21663510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]